Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are frequently used to treat depression during pregnancy and the postpartum period. These drugs are capable of crossing the placenta and being transferred to the newborn during lactation. This report reviews the available information regarding the effects of SSRIs on the fetus and newborn; including long-term neurodevelopmental outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Maternal depression and anxiety are two of the highest reported complications of pregnancy (Lattimore et al. 2005)”
From Pilot early intervention antenatal group program for pregnant women with anxiety and depression (2014) · cites this paper as Lattimore et al. 2005
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · cited 1×
“The lifetime risk for depression in women varies from 10 to 30%, with peak prevalence during the childbearing years.(1,2) Studies of postpartum depression suggest a 10 to 15% incidence in all parturients, making it one of the most common complications of pregnancy.”
Background(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
Depressive Symptoms among Pregnant Women Screened in Obstetrics Settings
Marcus, S. M., Flynn, H. A., Blow, F. C., & Barry, K. L. (2003) · Journal of Women's Health · doi:10.1089/154099903765448880 · Cited by 742 · cited 1×
“In addition, infants of chronically depressed mothers score inferiorly on the Bayley Mental and Motor Scales, achieve lower growth percentiles at 1 year of age,(4) and have delayed linguistic development and behavioral difficulties.(5) Depressed women have elevated levels norepinephrine and cortisol as markers of stre…”
BackgroundBirth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Depression and anxiety in early pregnancy and risk for preeclampsia
Kurki, T. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00602-x · Cited by 690
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612 · cited 1×
“This is their major advantage over the tricyclic antidepressants (TCA), and the reason for their increased tolerance and fewer adverse side effects.(12)”
BackgroundNeurodevelopment of Children Exposed in Utero to Antidepressant Drugs
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Gardner, H. A., Theis, J. G. W., Kulin, N., & Koren, G. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360404 · Cited by 573
Field, T. (1995) · Infant Behavior and Development · doi:10.1016/0163-6383(95)90003-9 · Cited by 524
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Pace-Asciak, P., Shuhaiber, S., & Koren, G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1889 · Cited by 441 · cited 4×
“Recently, in a prospective cohort trial, Nulman et al.34,36 evaluated IQ, language development, and temperament in children exposed to TCAs or SSRIs in the first trimester only, and also throughout pregnancy, compared to infants born to mothers who were not depressed and were not exposed to any known teratogenic medic…”
BackgroundResultInfluentialKulin, N. A., Pastuszak, A., Sage, S. R., Schick-Boschetto, B., Spivey, G., Feldkamp, M., Ormond, K., Matsui, D., Stein-Schechman, A. K., Cook, L., et al. (1998) · JAMA · doi:10.1001/jama.279.8.609 · Cited by 424
Casper, R. C., Fleisher, B. E., Lee-Ancajas, J. C., Gilles, A., Gaylor, E., DeBattista, A., & Hoyme, H. E. (2003) · The Journal of Pediatrics · doi:10.1067/mpd.2003.139 · Cited by 408 · cited 4×
“The study by Casper et al.(43) suggests that there may be subtle motor deficits in children with prenatal exposure to SSRIs.”
BackgroundResultInfluentialOutcomes of Prenatal Antidepressant Exposure
Simon, G. E., Cunningham, M. L., & Davis, R. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.12.2055 · Cited by 386
Placental Passage of Antidepressant Medications
Hendrick, V., Stowe, Z. N., Altshuler, L. L., Hwang, S., Lee, E., & Haynes, D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.5.993 · Cited by 380 · cited 2×
“Placental passage of antidepressants has also been documented in humans.(21,22) One study compared maternal serum concentrations of SSRIs to infant umbilical vein serum concentrations at birth.”
BackgroundPregnancy Outcome Following First-Trimester Exposure to Fluoxetine (Prozac)
Pastuszak, A. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500170076037 · Cited by 368
Neonatal-perinatal medicine: Diseases of the fetus and infant
Fanaroff, A. A., & Martin, R. J. (1977) · Medical Entomology and Zoology · Cited by 359
Orr, S. T. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf131 · Cited by 357 · cited 2×
“As noted previously, maternal depression during pregnancy has been associated with premature delivery and LBW.(7,9,10) Finally, all but one study compared SSRI-exposed women to healthy control populations with no psychiatric diagnosis.”
ResultSerotonin as a developmental signal
Whitaker-Azmitia, P. M., Druse, M., Walker, P., & Lauder, J. M. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00071-x · Cited by 356 · cited 2×
“Its exact role has yet to be well delineated, but it appears to autoregulate the development of serotonin neurons and aid in the development of other neurons, which produce neurotransmitters.(13) There have been many studies in rats to evaluate the fetal effects of prenatal exposure to fluoxetine, the prototype SSRI.”
BackgroundLaine, K., Heikkinen, T., Ekblad, U., & Kero, P. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.720 · Cited by 331 · cited 4×
“, anxiety).(41,49) As noted previously, maternal depression during pregnancy has been associated with premature delivery and LBW.”
BackgroundResultInfluentialPooled Analysis of Antidepressant Levels in Lactating Mothers, Breast Milk, and Nursing Infants
Weissman, A. M., Levy, B. T., Hartz, A. J., Bentler, S., Donohue, M., Ellingrod, V. L., & Wisner, K. L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1066 · Cited by 329 · cited 4×
“Postpartum depression occurs in 10 to 15% of mothers, and half of affected women are treated with pharmacotherapy.51 Weissman et al.51 recently reported a pooled analysis of 57 published and unpublished studies looking at antidepressant levels in lactating women, breast milk, and nursing infants.”
BackgroundInfluentialRole of Anxiety and Depression in the Onset of Spontaneous Preterm Labor
Dayan, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.4.293 · Cited by 322
Prenatal depression effects on neonates
Lundy, B. L., Jones, N. A., Field, T., Nearing, G., Davalos, M., Pietro, P. A., Schanberg, S., & Kuhn, C. (1999) · Infant Behavior and Development · doi:10.1016/s0163-6383(99)80009-5 · Cited by 320 · cited 1×
“Depressed women have elevated levels norepinephrine and cortisol as markers of stress response, as do their infants in the immediate newborn period, suggesting an in utero effect.(6) Women who are depressed during pregnancy have more obstetrical complications, such as premature delivery, preterm onset of labor, low bi…”
BackgroundHoffman, S., & Hatch, M. C. (2000) · Health Psychology · doi:10.1037//0278-6133.19.6.535 · Cited by 317 · cited 2×
“As noted previously, maternal depression during pregnancy has been associated with premature delivery and LBW.(7,9,10) Finally, all but one study compared SSRI-exposed women to healthy control populations with no psychiatric diagnosis.”
ResultNeonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy
Källén, B. (2004) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.158.4.312 · Cited by 300 · cited 2×
“This is consistent with results recently published by Kallen.28 This study utilized the large Swedish Medical Database.”
ResultDelivery outcome after the use of antidepressants in early pregnancy
Ericson, A., Källén, B., & Wiholm, B.-E. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050664 · Cited by 284
Maternal Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Newborn Neurobehavior
Zeskind, P. S., & Stephens, L. E. (2004) · Pediatrics · doi:10.1542/peds.113.2.368 · Cited by 280
Perinatal Outcome Following Third Trimester Exposure to Paroxetine
Costei, A. M., Kozer, E., Ho, T., Ito, S., & Koren, G. (2002) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.156.11.1129 · Cited by 270 · cited 1×
“, anxiety).(41,49) As noted previously, maternal depression during pregnancy has been associated with premature delivery and LBW.”
BackgroundBurke, K. C. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330013002 · Cited by 263 · cited 1×
“The lifetime risk for depression in women varies from 10 to 30%, with peak prevalence during the childbearing years.(1,2) Studies of postpartum depression suggest a 10 to 15% incidence in all parturients, making it one of the most common complications of pregnancy.”
BackgroundOberlander, T. F., Misri, S., Fitzgerald, C. E., Kostaras, X., Rurak, D., & Riggs, W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0214 · Cited by 244 · cited 12×
“Table 3 shows the results of the meta-analysis and lists the odds ratios (OR) and 95% confidence intervals (CI) for neonatal factors significantly impacted by in utero exposure to SSRIs.”
BackgroundResultInfluentialEinarson, A., Fatoye, B., Sarkar, M., Lavigne, S. V., Brochu, J., Chambers, C., Mastroiacovo, P., Addis, A., Matsui, D., Schuler, L., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1728 · Cited by 240 · cited 3×
“Its exact role has yet to be well delineated, but it appears to autoregulate the development of serotonin neurons and aid in the development of other neurons, which produce neurotransmitters.13 There have been many studies in rats to evaluate the fetal effects of prenatal exposure to fluoxetine, the prototype SSRI.”
BackgroundInfluentialAntidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 1×
“SSRI discontinuation syndromes have been described in the adult population with symptoms that commonly include dizziness, parasthesias, electric shock-like sensations, lethargy, headache, tremor, sweating, anorexia, insomnia, nausea, vomiting, diarrhea, irritability and anxiety, or agitation.(25) The syndromes have pr…”
BackgroundBirth outcomes after prenatal exposure to antidepressant medication
Hendrick, V., Smith, L. M., Suri, R., Hwang, S., Haynes, D., & Altshuler, L. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.172 · Cited by 209 · cited 1×
“The majority have noted an increase incidence of transitional difficulties in the neonatal period with no one diagnosis predominating.(20,27,37,42,44) Most of the aforementioned studies were of small sample size, making definitive interpretation difficult.”
BackgroundPharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation
Heikkinen, T. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(02)17634-x · Cited by 209 · cited 3×
“Heikkinen et al.(23,55) found no concerning adverse events in the immediate neonatal period and no difference in body weight or neurodevelopment at 1 year in infants exposed to fluoxetine and citalopram prenatally and through lactation compared to nonexposed control infants.”
BackgroundCitalopram in pregnancy and lactation
Heikkinen, T., Ekblad, U., Kero, P., Ekblad, S., & Laine, K. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126181 · Cited by 181 · cited 4×
“Heikkinen et al.(23,55) found no concerning adverse events in the immediate neonatal period and no difference in body weight or neurodevelopment at 1 year in infants exposed to fluoxetine and citalopram prenatally and through lactation compared to nonexposed control infants.”
BackgroundInfluentialNeonatal-Perinatal Medicine: Diseases of the Fetus and Infant
Taylor, P. M. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410170128059 · Cited by 176
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
Effects of First-Trimester Fluoxetine Exposure on the Newborn
Goldstein, D. (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00070-7 · Cited by 138
Birth outcomes following prenatal exposure to fluoxetine
Cohen, L. S., Heller, V. L., Bailey, J. W., Grush, L. R., Ablon, J. S., & Bouffard, S. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00877-5 · Cited by 137 · cited 1×
“The majority have noted an increase incidence of transitional difficulties in the neonatal period with no one diagnosis predominating.(20,27,37,42,44) Most of the aforementioned studies were of small sample size, making definitive interpretation difficult.”
BackgroundProlonged Prenatal Psychotropic Medication Exposure Alters Neonatal Acute Pain Response
Oberlander, T. F., GRUNAU, R. E., Fitzgerald, C., Ellwood, A.-L., Misri, S. K., Rurak, D. W., & Riggs, K. W. (2002) · Pediatric Research · doi:10.1203/00006450-200204000-00008 · Cited by 134 · cited 4×
“Oberlander et al.27 evaluated serum drug concentrations in 46 infants with late in utero exposure to SSRIs and found no correlation between infant drug levels in symptomatic infants with poor neonatal adaptation versus nonsymptomatic infants.27 Despite the frequency of side effects reported in the literature, cohort s…”
BackgroundInfluentialFluoxetine and norfluoxetine concentrations in nursing infants and breast milk
Hendrick, V. C., Stowe, Z. N., Altshuler, L. L., Mintz, J., Hwang, S., Hostetter, A. L., Suri, R., Leight, K. L., & Fukuchi, A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01197-0 · Cited by 126 · cited 1×
“Peak breast milk concentrations for sertraline and fluoxetine (and its metabolite norfluoxetine) occur 8 to 9 hours after maternal dosing”
BackgroundBerle, J. Ø., Steen, V. M., Aamo, T. O., Breilid, H., Zahlsen, K., & Spigset, O. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0911 · Cited by 117 · cited 2×
“There was no increase in adverse symptoms in drugexposed infants compared to a nonexposed group.(52) Several studies have sought to establish the peak drug concentration in breast milk after maternal dosing as a strategy to minimize infant exposure.”
BackgroundResultEffects of Third Trimester Fluoxetine Exposure on the Newborn
Goldstein, D. J. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00005 · Cited by 115
ADDIS, A., & KOREN, G. (2000) · Psychological Medicine · doi:10.1017/s0033291799001270 · Cited by 115 · cited 1×
“A meta-analysis of several smaller studies has documented that the use of SSRIs during the first trimester of pregnancy does not increase the risk of congenital malformations above that seen in the general population.(19) One study did note an increased incidence of three or more minor congenital malformations in infa…”
ResultWeight Gain in Infants Breastfed by Mothers Who Take Fluoxetine
Chambers, C., Anderson, P. O., Thomas, R. G., Dick, L. M., Felix, R. J., Johnson, K. A., & Jones, K. L. (1999) · PEDIATRICS · doi:10.1542/peds.104.5.e61 · Cited by 107 · cited 2×
“Chambers et al.(56) found a small growth deficit in fluoxetineexposed infants at 6 months of age.”
BackgroundStowe, Z. N., Hostetter, A. L., Owens, M. J., Ritchie, J. C., Sternberg, K., Cohen, L. S., & Nemeroff, C. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0114 · Cited by 92
The impact of depression and fluoxetine treatment on obstetrical outcome
Suri, R., Altshuler, L. L., Hendrick, V. C., Rasgon, N., Lee, E., & Mintz, J. (2004) · Archives of Women s Mental Health · doi:10.1007/s00737-004-0057-5 · Cited by 81 · cited 3×
“Low or decreased birth weight after in utero exposure to SSRIs was noted in three studies,28–30 but no difference was found in several other studies.31–37 Similarly, several reports have documented a tendency for infants exposed to SSRIs to have decreased gestation and/or a higher incidence of premature birth,20,28–30…”
MethodResultHansson, S. R., Mezey, É., & Hoffman, B. J. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00281-4 · Cited by 80
Costa, L. G., Steardo, L., & Cuomo, V. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.5 · Cited by 77 · cited 8×
“in the density of 5-HT transporters.(15) The limbic system appears particularly vulnerable to the effects of fluoxetine exposure in utero.”
BackgroundInfluentialObstetric complications in patients with depression — a population-based case–control study
Preti, A., Cardascia, L., Zen, T., Pellizzari, P., Marchetti, M., Favaretto, G., & Miotto, P. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00185-8 · Cited by 76 · cited 2×
“As noted previously, maternal depression during pregnancy has been associated with premature delivery and LBW.(7,9,10) Finally, all but one study compared SSRI-exposed women to healthy control populations with no psychiatric diagnosis.”
ResultHeikkinen, T. (2002) · BJOG: An International Journal of Obstetrics and Gynaecology · doi:10.1016/s1470-0328(02)01467-2 · Cited by 71 · cited 4×
“Placental passage of antidepressants has also been documented in humans.(21,22) One study compared maternal serum concentrations of SSRIs to infant umbilical vein serum concentrations at birth.”
BackgroundInfluentialCabrera-Vera, T. M., & Battaglia, G. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37746-8 · Cited by 67 · cited 1×
“The limbic system appears particularly vulnerable to the effects of fluoxetine exposure in utero.(16) There is also some evidence to suggest that 5-HT may play an indirect, but critical role in processing sensory stimuli,(17) and the 5-HT transporter may play an integral part in molding human behavior and neurodevelop…”
BackgroundPlacental transfer and fetal distribution of fluoxetine in the rat
Pohland, R. C., Byrd, T. K., Hamilton, M., & Koons, J. R. (1989) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(89)90225-1 · Cited by 65 · cited 1×
“Both fluoxetine and its active metabolite, norfluoxetine, cross the placenta and enter fetal brain tissue.(14) Studies to evaluate the neurochemical toxicity of fluoxetine on the developing fetal rat have demonstrated both age-specific and site-specific alterations in brain 5-HT content, 5-HT2A/2C receptor density, an…”
BackgroundNeonatal paroxetine withdrawal syndrome or actually serotonin syndrome?
ISBISTER, G. K., DAWSON, A., WHYTE, I. M., PRIOR, F. H., CLANCY, C., & SMITH, A. J. (2001) · Archives of Disease in Childhood - Fetal and Neonatal Edition · doi:10.1136/fn.85.2.f145g · Cited by 59
Psychopharmacology and Women: Sex, Gender, and Hormones
Perez, C. B. (1997) · Psychosomatics · doi:10.1016/s0033-3182(97)71509-3 · Cited by 57
Anderson, G. M. (2004) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.06.006 · Cited by 55 · cited 1×
“There is also some evidence to suggest that 5-HT may play an indirect, but critical role in processing sensory stimuli,(17) and the 5-HT transporter may play an integral part in molding human behavior and neurodevelopment.(18) These findings lead to a hypothetical concern for adverse human fetal brain development and…”
BackgroundParoxetine Use Throughout Pregnancy: Does It Pose Any Risk to the Neonate?
Morag, I., Batash, D., Keidar, R., Bulkowstein, M., & Heyman, E. (2004) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-120028753 · Cited by 21 · cited 1×
“A recently published case report also described an infant with an attenuated pain response and an abnormal EEG suggestive of encephalopathy, who had been exposed to paroxetine in utero.(58) The infant subsequently had a normal pain response and normal EEG at 2 weeks of life without intervention.”
Background
Research works printed but not linked: 6
- Zeskind PS, Stephens LE . Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368–375. · DOI · Paper page
- Costei AM, Kozer E, Ho T, Ito S, Koren G . Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129–1132. · DOI · Paper page
- Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188:812–815. · DOI · Paper page
- Chambers C, Dick LM, Felix RJ, Johnson KA, Jones KL . Pregnancy Outcome in women who use sertraline. Teratology 1999;59:376.
- Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246–2248. · DOI · Paper page
- Zeskind PS, Oberlander TF, Grunau RE, et al. Continuing effects of prenatal SSRI exposure detected by spectral analysis of infant cry sounds at two months of age. Pediatr Res 2005;57:1624A.
Cited by
Donofrio, M. T., Moon-Grady, A. J., Hornberger, L. K., Copel, J. A., Sklansky, M. S., Abuhamad, A., Cuneo, B. F., Huhta, J. C., Jonas, R. A., Krishnan, A., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437597.44550.5d · Cited by 1,275
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“neonatal adaptation syndrome (PNAS) [1121-1123], while”
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“, 2006) malformations, but one found evidence that SSRI use late in pregnancy was associated with subtle adverse effects (serotonergic overstimulation, withdrawal syndromes, long term neurobehavioural effects) in newborns (Lattimore et al., 2005).”
Background
Metadata
- Authors
- Lattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Perinatology
- Published
- 2005-07-14
- Volume
- 25
- Issue
- 9
- Pages
- 595-604
- ISSN
- 0743-8346 (ISSN-L)
- 1476-5543
- OpenAlex
- W2040155286
- Cited by
- 189
- References
- 55
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 14 · 2020: 6 · 2019: 14 · 2018: 9 · 2017: 13 · 2016: 7 · 2015: 11 · 2014: 11 · 2013: 17 · 2012: 15
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Perinatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (MH065062, R21MH065062, MH068489, R21MH068489)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
- Keywords
- selective serotonin reuptake inhibitors, pregnancy, fetal effects, neonatal outcomes, placental transfer, breastfeeding, maternal depression, postpartum depression, neurodevelopmental outcomes, antidepressant safety
- MeSH terms
- Child Development, Female, Fetus, Humans, Infant, Newborn, Maternal-Fetal Exchange, Pregnancy, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.